An observational study in Cystinosis, Nephropathic Cystinosis and Renal Fanconi Syndrome, sponsored by Cystinosis Research Foundation. Status unknown at 1 site in United States. Per ClinicalTrials.gov, last updated 2014-03-12.
Sponsored by Cystinosis Research Foundation · Observational
Cure Cystinosis International Registry (CCIR) is an online, patient self-identifying registry developed by medical and scientific experts specifically for the cystinosis community.
CCIR's sole purpose is to identify people with cystinosis worldwide in an effort to accelerate novel treatments and a cure for cystinosis.
CCIR provides a safe and secure platform for:
Interested cystinosis patients may register themselves with CCIR online at http://www.cystinosisregistry.org.
* No personal information is shared outside of CCIR. Individual identities are known only to appropriate CCIR staff. If a participant is matched to a clinical trial, the participant receives a notice from CCIR, after which they can decide whether they wish to contact the study sponsor.
Significance and Purpose:
Many different resources and tools are necessary to make significant advances in medical research. Progress in rare diseases such as cystinosis can often be impeded by the lack of information available about the disease and limited access to volunteers eligible for clinical trials. Therefore, patients who are willing to provide information about how the disease has affected them and also make themselves available to participate in trials are among the most valuable resources the investigators have to fight a disease. However, the research community desperately needs the right tool that will permit access to these resources.
A tool widely used to conveniently collect both data about a disease and information about potential clinical trial participants is a patient registry. A patient registry is any system that allows for the organized collection of data about disease outcomes in affected populations for a scientific, clinical, or policy purpose. The Cystinosis Research Foundation (CRF) has aligned itself with cystinosis medical experts and organizations worldwide to create the first ever international, online patient registry for cystinosis, Cure Cystinosis International Registry (CCIR). The express purpose of CCIR is to make anonymous information available to the research community and thus promote accelerated research in advanced treatments and ultimately a cure for cystinosis.
Objectives:
The objectives of CCIR are:
CCIR Registration:
Interested cystinosis patients may register themselves with CCIR online at http://www.cystinosisregistry.org. Registration is easy and secure. Simply go to the website and create a CCIR account and complete a survey. The CCIR website is currently available in English and Spanish, and will soon be available in French, Portuguese, and possibly other languages.
Benefits to CCIR participants include instant access to the registry's accumulated survey results (reported as anonymous group data), and opportunities to submit questions to cystinosis experts and to learn of clinical trial opportunities. No personal information is shared outside of CCIR. Individual identities are known only to appropriate CCIR staff.
72 studies on the registry are indexed under Fanconi Syndrome; 11 are open to participants now.
This study's planned enrollment of 750 is above the median of 53 across 20 observational studies indexed under Fanconi Syndrome.
Browse Fanconi Syndrome studies →This is the only study on the registry with Cystinosis Research Foundation as lead sponsor.
Counted across the registry records on this site, refreshed daily.
International cystinosis community
Inclusion Criteria:
Those with a diagnosis of cystinosis.
Age at treatment initiation and the effect on disease outcomes
Time frame: Lifetime
This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.